Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Director | January 30, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date January 30, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-30 | Direct | 6,000 |
Reported balance
After 2024-01-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-30 · Grant · Acquired 6,000 · Balance 6,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. |
| Common StockSEC Table I · non-derivative | Direct | 611 |
Reported balance
Holding disclosure · report date 2024-01-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 611 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2024 Filed Jan 31, 2024 21:25 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-24-002480 · doc4.xml · derivative · entry 2 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:24 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-061919 · doc4.xml · derivative · entry 2 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-12-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 00:05 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-003469 · doc4.xml · derivative · entry 2 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:33 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-18-016689 · doc4.xml · derivative · entry 2 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-02-29 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| May 02, 2017 Filed May 3, 2017 20:08 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 11,000 | $2.71 | $29,810.00 |
DisclosureSEC source: 0001209191-17-029621 · doc4.xml · nonDerivative · entry 1 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $2.65 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:53 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012763 · doc4.xml · derivative · entry 1 MITCHELL DANIEL J · CIK 0001113661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2017. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.